Intradermal COVID vaccination studies are emerging in a global effort to multiply available doses by harnessing skin immunity to reduce dosage required for effective vaccination.
| NES ZIONA, Israel and SHANGHAI, China, Feb. 7, 2022 /PRNewswire/ -- Intradermal COVID vaccination studies are emerging in a global effort to multiply available doses by harnessing skin immunity to reduce dosage required for effective vaccination. In a hallmark study published recently by IMB scientists[1], subjects were immunized twice with IMB’s inactivated SARS-CoV-2 vaccine intramuscularly. About six months later, 20 participants randomly received 1/15 (<7%) of the vaccine dose intradermally (into the skin) using NanoPass’s MicronJet™600 device. Significant increases in antibody levels were demonstrated one week and 2 months after the injection (X8-10 and X12.5-97 than baseline, respectively). Six months later, antibody levels were reduced but remained significantly higher than baseline (X8.5-12). These results have shown that the intradermal 3rd boost allowed for robust and sustained (>6mo) immunogenicity with a favorable safety (no fever and only mild injection site redness and swelling). NanoPass CEO, Dr. Yotam Levin says: “We commend the Chinese researchers for their continued pioneering work during COVID-19, in an effort to develop, evaluate and improve vaccines against this horrible pandemic. Excitingly, the study design used a mere 1/15 of the dose, potentially allowing to multiply available doses by 15-fold, and has demonstrated durability of response for at least six months. The study was conducted with the MicronJet™600 injection device, which is registered in China and most major markets, and which provides consistent intradermal inoculation.” This milestone is a joint effort between NanoPass and YNC, who supported IMB. YNC has been working hard to promote NanoPass’s intradermal delivery platform in China and this cooperation is a major milestone on the track to helping China combat COVID-19. YNC CEO, Ni Jian, says: China has made significant achievements in combatting COVID, however, the antibodies drop to a significantly low level six months after immunization, which provides a hotbed for the recurrence of the pandemic. This means that finding a way to improve antibody levels and sustaining such high levels for a longer time becomes critical. Through the reliability and consistency of the MicronJet™600 device for intradermal injections, IMB, with our support, has found a method to significantly increase the antibody levels (by 8 to 97 fold) and keep it at a high levels for at least six months. This milepost discovery and follow-up study are expected to provide important weapons for the global victory over COVID-19. About NanoPass: About YNC: [1] Fan S, et al. “Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine”. Vaccine. 2021 Nov 26;39(48):6980-6983. SOURCE NanoPass |
View original content:
